Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Dec;83(3):285-91.
doi: 10.1016/s0020-7292(03)00260-1.

Dysmenorrhea treatment with a single daily dose of rofecoxib

I Sahin  1 , F Saraçoğlu, Y Kurban, B Türkkani
Affiliations
Clinical Trial

Dysmenorrhea treatment with a single daily dose of rofecoxib

I Sahin et al. Int J Gynaecol Obstet. 2003 Dec.

Abstract

Objectives: To investigate the efficacy of single daily doses of rofecoxib, a selective inhibitor of cyclooxygenase-2, in dysmenorrhea.

Methods: Fifty-five patients were included in this randomized, placebo-controlled, cross-over study. Patients were randomized to use placebo, naproxen sodium (550 mg), 25 and 50 mg doses of rofecoxib in various orders. Pain intensity, analgesic efficacy of drugs, total number of pills used and side effects were evaluated.

Results: Rofecoxib with daily single doses of 25 and 50 mg decreased the pain intensity in a manner similar to naproxen sodium. Most of the patients (85.45% and 96.46%) evaluated the analgesic efficacy of rofecoxib as 'perfectly effective'. Rofecoxib was found to be effective for pain relief both in primary and secondary dysmenorrhea. Gastrointestinal adverse effects were less than those with naproxen sodium.

Conclusions: A 'one a day' dose of 25 mg rofecoxib is an effective choice with lower gastrointestinal adverse effects than naproxen sodium.

PubMed Disclaimer

MeSH terms